Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood

Vasileios G. Bampalis; Anna L. Khandoga; Wolfgang Siess

doi:10.1160/TH10-05-0313

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 104(06): 1272-1274
DOI: 10.1160/TH10-05-0313

Letters to the Editor

Schattauer GmbH

Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood

Authors

Vasileios G. Bampalis

¹Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany
Anna L. Khandoga

¹Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany
Wolfgang Siess

¹Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany

Abstract

Full Text

References

References
1 de Abajo FJ, Montero D, Rodriguez LA. et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-310.
2 Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 2007; 32: 23-29.
3 Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?. Am J Cardiovasc Drugs 2003; 3: 149-162.
4 Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119-128.
5 McCloskey DJ, Postolache TT, Vittone BJ. et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151: 168-172.
6 Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-462.
7 Li N, Wallen NH, Ladjevardi M. et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523.
8 Bevan J, Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res 1985; 38: 189-194.
9 De Clerck FF, Janssen PA. Amplification mechanisms in platelet activation and arterial thrombosis. J Hypertens Suppl 1990; 8: S87-93.
10 Galan AM, Lopez-Vilchez I, Diaz-Ricart M. et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511-519.
11 Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.
12 Dalton SO, Johansen C, Mellemkjaer L. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
13 Gartner R, Cronin-Fenton D, Hundborg HH. et al. Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study. BMC Surg 2010; 10: 3.
14 Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-1898.
15 Tata LJ, West J, Smith C. et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-471.
16 Blanchette CM, Simoni-Wastila L, Zuckerman IH. et al. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol 2008; 18: 316-321.
17 Carneiro AM, Cook EH, Murphy DL. et al. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008; 118: 1544-1552.
18 Dilks JR, Flaumenhaft R. Fluoxetine (Prozac) augments platelet activation mediated through pro-tease-activated receptors. J Thromb Haemost 2008; 6: 705-708.
19 Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60: 1710-1713.
20 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
21 Walther DJ, Peter JU, Winter S. et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
22 De Clerck F, Xhonneux B, Leysen J. et al. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-2811.
23 Knight AR, Misra A, Quirk K. et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 114-123.
24 Glusa E, Markwardt F. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents. Biomed Biochim Acta 1984; 43: 215-220.
25 Bevan J, Heptinstall S. Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation. Naunyn Schmiedebergs Arch Pharmacol 1986; 334: 341-345.